Capstan Medical Raises $31.4M Series B To Progress Heart Valve Tech Into Human Trials

The heart tech company plans to use the new funding to test its robotics- and catheter-based solution for treating mitral and tricuspid valve disease in humans.

Heart Valve
• Source: Shutterstock (Shutterstock)

Heart tech company Capstan Medical announced on 9 August it raised $31.4m in a series B round of funding, led by venture capital firm Eclipse with participating investors including Intuitive Ventures and Puma Venture Capital.

The Santa Cruz, CA-based company plans to use the newly raised monies to expand its engineering, clinical development and operations teams in preparation for human trials of Capstan’s technology for...

More from Financing

More from Business